Corporate Ranking - A New Order For 1995
1995 could be classified as a year of musical chairs as far as corporate ranking in the pharmaceutical industry is concerned, and 1996 has started in the same vein, particularly with the planned merger of Swiss giants Ciba and Sandoz.
The dramatic changes in position seen in 1995 (see table opposite page) can be attributed in part to the merger and acquisition strategies being operated by several companies, according to a preview of IMS International Pharmaceutical World Review data, which covers 47 countries, including the top 10 markets.
The review indicates that worldwide sales have grown by 13% (8% in local currency terms) to $205 billion for 1995, compared with 7% growth (6% at local currency levels) during 1994.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze